AstraZeneca PLC $AZN Shares Bought by Sound View Wealth Advisors Group LLC

Sound View Wealth Advisors Group LLC raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 5.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,534 shares of the company’s stock after buying an additional 2,245 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in AstraZeneca were worth $3,182,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Robbins Farley acquired a new stake in AstraZeneca during the second quarter worth approximately $1,857,000. SCS Capital Management LLC purchased a new position in shares of AstraZeneca in the 1st quarter valued at $3,066,000. Jennison Associates LLC lifted its position in AstraZeneca by 15.2% in the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after acquiring an additional 1,605,133 shares during the last quarter. Oliver Luxxe Assets LLC boosted its stake in AstraZeneca by 6.0% in the second quarter. Oliver Luxxe Assets LLC now owns 78,301 shares of the company’s stock valued at $5,472,000 after acquiring an additional 4,449 shares in the last quarter. Finally, Alhambra Investment Management LLC purchased a new position in shares of AstraZeneca during the second quarter worth about $320,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the subject of several research reports. Jefferies Financial Group initiated coverage on AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Stock Up 1.0%

AZN opened at $84.58 on Friday. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $86.57. The business has a 50 day moving average price of $81.41 and a two-hundred day moving average price of $75.55. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The company has a market cap of $262.32 billion, a PE ratio of 31.80, a P/E/G ratio of 1.52 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.05. The company had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company’s revenue was up 12.0% on a year-over-year basis. During the same period last year, the business posted $2.08 EPS. As a group, research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.